Restoring Immune Resolution in HIV Infection via Conditional IL-10 Expression: A CRISPR-Based Approach Derived from Parsimony Theory

Abstract

HIV-1 infection progressively depletes CD4+ T-cells — the primary mediators of immune resolution — resulting in chronic immune activation, systemic inflammation, and eventual collapse of adaptive immunity. Current antiretroviral therapy suppresses viral replication but does not restore the immune system's capacity for self-resolution. We propose that HIV pathogenesis is fundamentally a disruption of the immune activation-resolution cycle, and that restoring the missing resolution step — independently of CD4+ T-cell count — represents a more parsimonious therapeutic target than viral elimination alone.

We describe a CRISPR-based intervention in which a subset of autologous T-cells is engineered to express interleukin-10 (IL-10) under the control of an NFAT-responsive promoter, inserted at the AAVS1 safe harbor locus. This edit restores conditional immune resolution without constitutive immunosuppression.

1. Introduction

1.1 The limits of current treatment

Antiretroviral therapy has transformed HIV from a fatal disease into a manageable chronic condition. ART suppresses viral load to undetectable levels in adherent patients. However, ART does not cure HIV infection. Even in virally suppressed patients, chronic immune activation persists. Elevated inflammatory markers — IL-6, CRP, D-dimer — remain above healthy baseline and predict non-AIDS morbidity including cardiovascular disease, neurocognitive decline, and malignancy.

1.2 CD4 depletion as cycle disruption

CD4+ T-helper cells perform two critical functions: amplifying immune responses and mediating their resolution. HIV preferentially infects and depletes activated CD4+ T-cells, targeting precisely the cells responsible for resolving the responses they help initiate. The consequence is a system that can activate but cannot resolve.

1.3 The resolution gap

IL-10 is the principal anti-inflammatory cytokine responsible for immune resolution. In HIV infection, IL-10 production is dysregulated — elevated in quantity but impaired in timing and source. The result is a resolution signal that exists but cannot function: present in excess at the wrong time, absent at the right time.

2. Theoretical Framework

2.1 The immune response as a parsimonious cycle

1. recognize   — antigen detected, T-cell activates
2. respond     — effector response mounted
3. stand down  — resolution signal issued, response winds down
4. consolidate — memory formed, system returns to baseline

2.2 HIV as disruption of step 3

HIV does not prevent recognition or response — both remain intact and often hyperactivated. It selectively depletes the cell population responsible for issuing the stand-down signal, leaving the cycle structurally incomplete. Chronic immune activation, immune exhaustion, and eventual immune collapse follow directly.

2.3 The minimum intervention

Restore the stand-down signal independently of CD4+ T-cell count.

This is a narrower and more specific target than viral elimination. It does not require clearing the viral reservoir. It requires only that the immune system regain the capacity to resolve its own responses.

3. Proposed Intervention

3.1 Molecular design

Promoter: The NFAT (Nuclear Factor of Activated T-cells) promoter is activated downstream of T-cell receptor signaling — silent in resting T-cells, active within hours of antigen engagement.

Payload: Human IL-10 coding sequence, codon-optimized for T-cell expression.

Safe harbor: The AAVS1 locus (chromosome 19) — established safe harbor with no oncogenic risk, used in multiple approved cell therapies.

AAVS1 homology arm L
  NFAT promoter (6x NFAT binding sites + minimal promoter)
  → Kozak sequence
  → human IL-10 (codon-optimized)
  → WPRE (expression enhancer)
  → polyA signal
AAVS1 homology arm R

Delivery: Cas9 RNP + AAV6 donor template, electroporated into autologous T-cells ex vivo. Same platform as approved sickle cell therapies (CTX001/exa-cel).

3.2 Predicted mechanism

1. recognize   — antigen detected, edited T-cell activates
2. respond     — effector response mounted (unchanged)
3. stand down  — NFAT fires → IL-10 expressed → resolution signal present  ← RESTORED
4. consolidate — inflammation resolves, memory forms, baseline restored

4. Discussion

4.1 Testable predictions

1. Edited T-cells will express IL-10 in response to TCR stimulation in vitro, with expression returning to baseline after stimulation ends.

2. In HIV-infected humanized mouse models, reinfusion of edited T-cells will reduce markers of chronic immune activation (IL-6, TNF-α, PD-1, Tim-3) without impairing viral clearance.

3. CD4+ T-cell counts will stabilize or recover in treated animals, as activation-driven depletion is reduced.

4. The edited T-cell population will persist and expand in vivo, propagating the resolution-competent phenotype.

4.2 Limitations

This is a theoretical proposal. Key uncertainties include whether NFAT-driven IL-10 expression is sufficient to restore resolution at physiological cell frequencies, whether the edited population will persist long-term in an HIV-infected host, and long-term effects of sustained NFAT-IL-10 coupling across chronic infection.

5. Conclusion

HIV pathogenesis is the progressive loss of immune resolution capacity. The minimum intervention is not viral elimination — it is restoration of the stand-down signal, independently of the cells HIV destroys.

One cut. One insertion. One missing step restored.